MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515
This study is recruiting at 24 US sites in 17 states, according to its ClinicalTrials.gov record last updated .
Summary
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Pancreatic Ductal Adenocarcinoma
- Non-small Cell Lung Cancer
- Colorectal Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Eli Lilly and Company
- Last updated on ClinicalTrials.gov
- August 24, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- City of Hope · Duarte, CA
- University of California, Los Angeles (UCLA) · Santa Monica, CA
Colorado · 1
- Sarah Cannon Research Institute at HealthOne · Denver, CO
District of Columbia · 1
- Sibley Memorial Hospital · Washington D.C., DC
Florida · 1
- Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute · Orlando, FL
Georgia · 1
- Emory University School of Medicine · Atlanta, GA
Indiana · 1
- Community Health Network · Indianapolis, IN
Massachusetts · 1
- Dana-Farber Cancer Institute · Boston, MA
Michigan · 2
- Barbara Ann Karmanos Cancer Institute · Detroit, MI
- South Texas Accelerated Research Therapeutics (START) Midwest · Grand Rapids, MI
New York · 2
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center · New York, NY
- New York University (NYU) Langone Medical Center · New York, NY
North Carolina · 1
- Duke University Medical Center · Durham, NC
Ohio · 2
- University of Cincinnati (UC) - Cancer Institute · Cincinnati, OH
- Cleveland Clinic · Cleveland, OH
Pennsylvania · 1
- University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center · Pittsburgh, PA
Tennessee · 3
- Sarah Cannon Research Institute · Nashville, TN
- USO - US Oncology Research Network · Nashville, TN
- Vanderbilt University School of Medicine · Nashville, TN
Texas · 2
- MD Anderson Cancer Center · Houston, TX
- South Texas Accelerated Research Therapeutics (START) · San Antonio, TX
Utah · 1
- Huntsman Cancer Institute · Salt Lake City, UT
Washington · 1
- Fred Hutchinson Cancer Center · Seattle, WA
Wisconsin · 1
- University of Wisconsin - Carbone Cancer Center · Madison, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.